Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR8518272

· E

5851c5c4-19fd-505c-b508-65f37baf19a6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.310
  • SPERMATOGENESIS+0.270
  • PROTEIN_SECRETION+0.250
  • BILE_ACID_METABOLISM+0.170
  • KRAS_SIGNALING_DN+0.150
  • ADIPOGENESIS+0.140
  • PEROXISOME+0.120
  • FATTY_ACID_METABOLISM+0.090
  • ANDROGEN_RESPONSE+0.050
  • HEME_METABOLISM+0.020

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
  • ALLOGRAFT_REJECTION-0.460
  • COMPLEMENT-0.410
  • INFLAMMATORY_RESPONSE-0.410
  • G2M_CHECKPOINT-0.400
  • ANGIOGENESIS-0.390
  • IL6_JAK_STAT3_SIGNALING-0.360
  • INTERFERON_GAMMA_RESPONSE-0.350
  • COAGULATION-0.340
  • NOTCH_SIGNALING-0.340

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_9NJHQE9F
medullo-epn-umap@date-based
MedMedulloblastoma0.876
2SRR655134
brain-umap@2
GTEX0.875
3SAMN03290937
melanoma-umap@29
0.873
4SRR35579848
breast-umap@18
B0.869
5MBCProject_0343_T1_RNA
breast-umap@18
B0.855
6SRR10900001
melanoma-umap@29
0.855
7SRR1322555
brain-umap@2
GTEX0.850
8SRR2770872
melanoma-umap@29
0.847
9TCGA-B6-A0X4-01A-11R-A109-07
breast-umap@18
B0.847
10SRR1464327
brain-umap@2
GTEX0.846

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 11 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.310Remibrutinib— uncovered
SPERMATOGENESIS0.270Inavolisib— uncovered
PROTEIN_SECRETION0.250Remibrutinib— uncovered
BILE_ACID_METABOLISM0.170Inavolisib— uncovered
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered
ADIPOGENESIS0.140Inavolisib— uncovered
PEROXISOME0.120Idelalisib— uncovered
FATTY_ACID_METABOLISM0.090Inavolisib— uncovered
ANDROGEN_RESPONSE0.050Inavolisib— uncovered
HEME_METABOLISM0.020Temsirolimus— uncovered
MYOGENESIS0.020Inavolisib— uncovered